drugset
Drugs / ensovibep
last change Jul 2023 re-read 2 minutes ago

ensovibep

also known as MP0420

Protein / enzyme biologic

Developed for
COVID-19
Investigated by
Molecular Partners AG · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Cardiothoracic Surgical Trials Network · International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) · Kirby Institute · Medical Research Council
+14 more · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Allergy and Infectious Diseases (NIAID) · Prevention and Early Treatment of Acute Lung Injury · US Department of Veterans Affairs · University of Copenhagen · University of Minnesota · Washington D.C. Veterans Affairs Medical Center · AstraZeneca · Brii Biosciences Limited · Eli Lilly and Company · GlaxoSmithKline · Novartis Pharmaceuticals · Pfizer · Vir Biotechnology, Inc.

Trials 5 · a red edge is where a trial was stopped

today NCT05780463 · Ph 3 NCT04828161 · Ph 2/3 NCT04834856 · Ph 2 NCT04870164 · Ph 1 NCT04501978 · Ph 3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04870164 Nov 2020 → Jan 2022 COVID-19 Molecular Partners AG Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT04834856 Apr → Aug 2021 COVID-19 Molecular Partners AG Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04828161 May → Nov 2021 COVID-19 Novartis Pharmaceuticals Terminated No outcome recorded
Phase 32 trials
Phase 3 NCT05780463 Jun 2021 → Feb 2022 COVID-19 National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 3 NCT04501978 Aug 2020 → Apr 2022 COVID-19 National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2022-01-10 Novartis Pharmaceuticals Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 novartis.com ↗
2021-05-27 Novartis Pharmaceuticals Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 novartis.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as ensovibep ClinicalTrials.gov intervention name — accepted as the source's own label NCT04834856 ↗
2

NCT04828161 ↗

NCT04870164 ↗
Known as MP0420 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04501978 ↗
1

NCT05780463 ↗
Modality Protein / enzyme biologic “Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins” PMID 35939810 ↗ Aug 2022
1

CHEMBL4802171 ↗
Route Intravenous “INTERVENTION: Intravenous ensovibep, 600 mg, or placebo.” PMID 35939810 ↗ Aug 2022